An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes.

Trial Profile

An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2011

At a glance

  • Drugs Enoxaparin sodium; Fondaparinux sodium
  • Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms OASIS-5
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 May 2011 Actual initiation date (Apr 2003) added as reported by ClinicalTrials.gov.
    • 10 May 2011 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
    • 10 May 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top